PMC3317086_01
(a) Skin lesions of the patient showing on face and fingers. (b) Serum complement C3 levels and SLEDAI scores before rituximab therapy and at the end of the followup period.
ISRN.RHEUMATOLOGY2011-917673.001.jpg
PMC3317086_01_ISRN.RHEUMATOLOGY2011-917673.001.jpg
fig1
His clinical presentation included severe malar rash with marked photosensitivity and bullous lesions on the tips of fingers and hands (Figure 1). His complaints and laboratory values and SLEDAI scores were improved significantly after rituximab treatment, as shown in Figure 1(b).